Business Wire

New Study Evaluates the Ability of Masimo ORi™ to Help Clinicians Reduce Hyperoxemia in Mechanically Ventilated ICU Patients

Jaa

Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at the 2018 Congress of the French Society of Anesthesia and Resuscitation (SFAR) in Paris in which researchers at CHU Angers in France investigated the ability of Masimo ORi™ (Oxygen Reserve Index) to help clinicians reduce the number of days ICU patients experience hyperoxemia while on mechanical ventilation.1 ORi, available outside the U.S., is a noninvasive and continuous parameter intended as a relative indicator of a patient’s oxygen reserve during moderate hyperoxia (partial pressure of oxygen in arterial blood [PaO2] in the range of 100 to 200 mmHg). ORi can be trended and has optional alarms to notify clinicians of changes in oxygenation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180930005016/en/

Masimo Root® with Radical-7®, ORi™, and RD rainbow SET™ Sensor (Photo: Business Wire)

Masimo Root® with Radical-7®, ORi™, and RD rainbow SET™ Sensor (Photo: Business Wire)

Noting that hyperoxemia can lead to patient morbidity and mortality in ICU patients, and that oxygen saturation (SpO2) cannot detect hyperoxemia, Dr. Brochant and colleagues sought to evaluate whether ORi might be useful in helping clinicians determine when to reduce the fraction of inspired oxygen (FiO2) during oxygen therapy, so as to avoid hyperoxemia. In this initial analysis, the first 131 patients in the study, whose data were collected between May 2017 and March 2018, were randomly assigned into an ORi and a control group. In the ORi group, FiO2 was reduced if ORi was > 0. In the control group, the FiO2 level was adjusted according to SpO2. Clinicians recorded blood gas results, episodes of atelectasis, and the length of time spent on mechanical ventilation, for up to 28 days. The principal point of comparison was the proportion of ventilated days with hyperoxemia.

The researchers found that the percentage of days with hyperoxemia was significantly lower in the ORi group: median 14% [interquartile range 0-31%], vs. 29% [IQR 11-50%] in the control group, p=0.005. Average daily PaO2 and FiO2 values were not significantly different between the two groups, suggesting that FiO2 was not systematically lowered in the ORi group. The average number of days without ventilation and median time spent in the ICU were also not significantly different.

The researchers concluded that the use of ORi may help clinicians reduce the percentage of days with hyperoxemia, that analysis of the full group of patients may allow assessment of its effect on the occurrence of atelectasis, and that additional studies may be useful in evaluating the impact of this monitoring on the morbidity and mortality of patients.

ORi has not received FDA 510(k) clearance and is not available for sale in the United States.

@MasimoInnovates | #Masimo

Reference

  1. Brochant A, Dupre P, Gaillard T, Lemarie P, Gergaud S, and Lasocki S. “ORi pour moins d’hyperoxie en reanimation.” Proceedings from SFAR 2018, Paris, France. #R244.

About Masimo

Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,1 improve CCHD screening in newborns,2 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response activations and costs.3,4,5 Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world,6 and is the primary pulse oximetry at 9 of the top 10 hospitals listed in the 2018-19 U.S. News and World Report Best Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), and more recently, Oxygen Reserve Index (ORi™), in addition to SpO2, pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect® (MOC-9®) interface, enabling other companies to augment Root with new features and measurement capabilities. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7® wearable patient monitor, iSpO2 ® pulse oximeter for smartphones, and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at http://www.masimo.com/evidence/featured-studies/feature/.

ORi has not received FDA 510(k) clearance and is not available for sale in the United States.

The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

  1. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
  2. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
  3. Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-And-After Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
  4. Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
  5. McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
  6. Estimate: Masimo data on file.
  7. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo ORi. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo ORi, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Contact information

Masimo
Evan Lamb, 949-396-3376
elamb@masimo.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Denodo Offers Data Virtualization Test Drive on Microsoft Azure17.12.2018 11:30Tiedote

Denodo, the leader in data virtualization today announced the availability of a free Test Drive environment on Microsoft Azure. Following on the heels of its recently announced Test Drive on AWS, the newest Denodo Test Drive empowers users to quickly and easily create real-time data delivery without replication and explore the benefits of using the Denodo Platform on Azure. Denodo Test Drives are completely free of charge for demonstration, education and evaluation purposes and are available at: http://bit.ly/2AQddE3 Built on Azure, the Test Drive lets individuals discover, explore, prepare, and access data in a user-friendly interface for true self-service. The Denodo Test Drive solves some of the most pressing challenges faced by data scientists and data analysts by enabling them to integrate large volumes of data to support their agile BI, big data analytics and Web/cloud integration objectives. “Microsoft’s commitment to offer an ecosystem of cloud solutions makes it ideal for Deno

Arthur D. Little Report Outlines €200 Billion Digital Transformation Opportunity for Telecoms Sector17.12.2018 11:30Tiedote

Arthur D. Little (ADL) today published a new research report highlighting the need for greater digitalization in the global telecoms industry. The TIME 2018 Flagship Report outlines the scale of the digital opportunity, with analysis estimating that a ‘digital dividend’ of over €200 billion free cash flow awaits telcos that can successfully transform. Industry executives surveyed for the report confirm the findings. 73% say that digital will add value to their businesses, with key benefits including greater agility, increased subscriber growth and cost savings. CAPEX spending on areas such as 5G infrastructure and the Internet of Things is expected to require a 7% CAGR increase from 2017-2022, outpacing forecast revenue growth. Consequently, failing to digitally transform risks commoditization and disintermediation, leaving telcos unable to invest sufficiently. As one senior executive put it bluntly, “Digitalization – there is no other choice if we want to survive.” The report highligh

Arthur D. Little Global Automotive Study Outlines Importance of Car in Changing World of Mobility17.12.2018 11:30Tiedote

Arthur D. Little (ADL) today released its worldwide automotive market report. Key findings are that desire for car ownership remains strong, especially amongst the young, and that drivers are considering a dramatic switch to electric and hybrid vehicles (EVs). This will impact manufacturer and supplier engine strategies and push for faster development of EV ecosystems, such as charging solutions. Drivers are now much more willing to embrace alternative drivetrains. 58% would accept paying more for hybrids, and 50% for EVs. While the majority have petrol or diesel-engined vehicles, this could change rapidly. Of those planning to replace their car, 48% said they’d consider an EV (BEV, hybrid or plugin hybrid), 36% a petrol-engined vehicle and 12% diesel. Klaus Schmitz, Partner with Arthur D. Little explains: “Extending our groundbreaking 2015 automotive study shows enormous changes. While attachment to car ownership remains high, meaning the overall automotive market will remain stable,

Montagu Evans Chooses MobileIron Cloud to Keep Client Data Safe on Mobile Devices17.12.2018 11:00Tiedote

MobileIron (NASDAQ:MOBL), the secure foundation for modern work, today announced that Montagu Evans has selected MobileIron unified endpoint management (UEM) cloud solution, including MobileIron Access and MobileIron Threat Defense. For nearly a century, Montagu Evans, a partnership and one of UK’s largest owner-managed surveying firms, has helped its clients shape some of UK’s largest commercial, residential and mixed-use property development projects. With increasingly sensitive client work, more employees on job sites using mobile devices, and the newly enforced GDPR, it was imperative for Montagu Evans to use a best-in-class UEM solution to securely manage all data without compromising productivity. Safety from Mobile Threats Since Montagu Evans’ employees often need to connect through unsecured networks, such as public Wi-Fi networks, the company needed to ensure that highly sensitive customer information could not be intercepted or compromised. To solve this problem, Montagu Evan

Safebridge Takes Maritime Certification into The Digital Era with myCert17.12.2018 11:00Tiedote

Safebridge expands its product portfolio with the launch of myCert, an innovative digital platform which utilises the blockchain technology to provide a secure online environment and upgrade the entire maritime certification ecosystem. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181217005042/en/ myCert – the first digital solution for maritime certificates (Photo: Safebridge) myCert connects three main components: the entities who issue certificates, the seafarers who hold and need those certificates in their everyday activity and the verifiers who can be virtually anyone wishing to verify the validity of the certificates. myCert is the solution for professional users to better manage the life cycle of certificates, by having control over them from one single platform, securely and with 24/7 availability worldwide. “We saw Safebridge’s myCert in action at INTERTANKO’s Seafarers’ Vetting Seminar, in the Philippines. Over 1

Price f(x) Files Petitions with US Patent and Trademark Office to Invalidate Vendavo’s Patents and Launches a Counter Lawsuit17.12.2018 10:08Tiedote

Price f(x), the global leader in cloud pricing software, has filed petitions for “Covered Business Method (“CBM”) Review” of four Vendavo patents, and will imminently file a fifth, which together will cover challenges to all of the patent claims that Vendavo has asserted in litigation between the parties. In Price f(x)’s view, each of Vendavo’s patents qualifies for the specialized CBM procedure created by US Congress to “crackdown on low-quality business method patents.” Price f(x)’s petitions challenge Vendavo’s patents on a variety of grounds, including in all cases that the claims are directed to patent-ineligible abstract ideas (e.g., math for pricing of products), and in many cases that Vendavo simply tried to claim more than it actually invented. The petitions are now pending in the U.S. Patent Office, which should make an initial ruling on Price f(x)’s petitions in approximately six months. Price f(x) is concurrently moving to stay the patent portion of the parties’ litigation

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme